Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK146D1 + ivonescimab
- Development stage
- Phase 2
- Lead developer
- Akeso
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AK146D1 + Yidafang is an investigational combination regimen consisting of AK146D1, a bispecific antibody-drug conjugate (bsADC) targeting TROP2 and Nectin-4, and Yidafang (ivonescimab), an approved bispecific antibody targeting PD-1 and VEGF-A. Developed by Akeso, this combination is part of the company's 'IO2.0 + ADC2.0' strategy, which aims to combine next-generation immuno-oncology agents with bispecific ADCs to overcome the limitations of conventional therapies. AK146D1 consists of a bispecific antibody targeting TROP2 and Nectin-4 conjugated to a topoisomerase I inhibitor (DXd) payload via a cleavable MC-AAA linker. Ivonescimab simultaneously blocks PD-1 and VEGF-A to restore T-cell activity and normalize the tumor microenvironment. The combination is currently being evaluated in Phase II clinical trials for advanced solid tumors, including non-small cell lung cancer (NSCLC), breast cancer (specifically HR+/HER2- and triple-negative breast cancer), and urothelial carcinoma.
- Brand names
- AK146D1 + Yidafang
- Other names
- AK146D1 and ivonescimabAK-146D1 and ivonescimabAK 146D1 and ivonescimabAK146D1 in combination with YidafangAK-146D1 in combination with YidafangAK 146D1 in combination with YidafangAK146D1 in combination with ivonescimabAK-146D1 in combination with ivonescimabAK 146D1 in combination with ivonescimab
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)PDCD1 (Programmed cell death protein 1 receptor)TACSTD2 (Tumor-associated calcium signal transducer 2)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on AK146D1 + ivonescimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK146D1 + ivonescimab.